Prevention of liver cancer cachexia-induced cardiac wasting and heart failure
von Haehling, Stephan
von Websky, Karoline
Coats, Andrew J.S.
Argiles, Josep M.
Anker, Stefan D.
MetadataShow full item record
AbstractAims Symptoms of cancer cachexia (CC) include fatigue, shortness of breath, and impaired exercise capacity, which are also hallmark symptoms of heart failure (HF). Herein, we evaluate the effects of drugs commonly used to treat HF (bisoprolol, imidapril, spironolactone) on development of cardiac wasting, HF, and death in the rat hepatoma CC model (AH-130). Methods and results Tumour-bearing rats showed a progressive loss of body weight and left-ventricular (LV) mass that was associated with a progressive deterioration in cardiac function. Strikingly, bisoprolol and spironolactone significantly reduced wasting of LV mass, attenuated cardiac dysfunction, and improved survival. In contrast, imidapril had no beneficial effect. Several key anabolic and catabolic pathways were dysregulated in the cachectic hearts and, in addition, we found enhanced fibrosis that was corrected by treatment with spironolactone. Finally, we found cardiac wasting and fibrotic remodelling in patients who died as a result of CC. In living cancer patients, with and without cachexia, serum levels of brain natriuretic peptide and aldosterone were elevated. Conclusion Systemic effects of tumours lead not only to CC but also to cardiac wasting, associated with LV-dysfunction, fibrotic remodelling, and increased mortality. These adverse effects of the tumour on the heart and on survival can be mitigated by treatment with either the β-blocker bisoprolol or the aldosterone antagonist spironolactone. We suggest that clinical trials employing these agents be considered to attempt to limit this devastating complication of cancer.
CitationSpringer, J. et al (2013) 'Prevention of liver cancer cachexia-induced cardiac wasting and heart failure' European heart journal 35(14):932-41
PublisherOxford University Press
JournalEuropean heart journal
PubMed Central IDPMC3977133
- Cardiac expression of neutrophil gelatinase-associated lipocalin in a model of cancer cachexia-induced cardiomyopathy.
- Authors: Musolino V, Palus S, Latouche C, Gliozzi M, Bosco F, Scarano F, Nucera S, Carresi C, Scicchitano M, von Haehling S, Jaisser F, Hasenfuss G, Anker SD, Mollace V, Springer J
- Issue date: 2019 Feb
- Megestrol acetate improves cardiac function in a model of cancer cachexia-induced cardiomyopathy by autophagic modulation.
- Authors: Musolino V, Palus S, Tschirner A, Drescher C, Gliozzi M, Carresi C, Vitale C, Muscoli C, Doehner W, von Haehling S, Anker SD, Mollace V, Springer J
- Issue date: 2016 Dec
- Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
- Authors: Fraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J
- Issue date: 2003 Nov 5
- Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats.
- Authors: Nakano S, Kobayashi N, Yoshida K, Ohno T, Matsuoka H
- Issue date: 2005 Nov
- Spironolactone alleviates late cardiac remodeling after left ventricular restoration surgery.
- Authors: Tsukashita M, Marui A, Nishina T, Yoshikawa E, Kanemitsu H, Wang J, Ikeda T, Komeda M
- Issue date: 2008 Jul